Leading Drug Fails to Slow Alzheimer’s Progression
(MedPage Today) — Alzheimer’s patients treated with the GLP-1 receptor agonist semaglutide (Rybelsus) in two phase III trials showed no significant improvement in cognitive or functional decline over 2 years compared with placebo, according to…
Weight loss drugs have great action, but can’t replace diet and exercise: Diabetes Federation president
“The new GLP-1 class of drugs comprises brilliant molecules that have very good action, but they are also very expensive”
Scientists Testing GLP-1s for Overweight Dogs and Cats
Your pet dog or cat might soon be a chubby little munchkin no more. Welcome to the burgeoning era of — we swear we’re not making this up — “ozempets,” in which your servile critters might shed some extra pounds by taking animal-focused diabetes and weight loss drugs similar to Ozempic and Wegovy. It hasn’t […]
Why Is Cencora (COR) Down 6.3% Since Last Earnings Report?
A month has gone by since the last earnings report for Cencora (COR). Shares have lost about 6.3% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Cencora due for a breakout? Well, first let’s […]
Stopping GLP-1s raises complicated questions for pregnancy
Using popular weight-loss drugs like Ozempic during pregnancy is not recommended. But stopping the medications just before conception or in the early stages of pregnancy may come with some risks, according to a new study. And without further studies, say experts, the data paints a complicated picture of the relationship between GLP-1s and pregnancy. What […]
The dual GLP-1–glucagon agonist pemvidutide in MASH: a phase 2b trial
Publication date: 6–12 December 2025 Source: The Lancet, Volume 406, Issue 10520 Author(s): Frank Tacke
What to know about GLP-1 drugs and muscle loss
A recent KFF poll revealed that one in eight adults in the U.S. is currently taking a GLP-1 weight loss drug. As more people start using them, some are talking about the unexpected side effects, including muscle loss and weakness. Senior Vox correspondent Dylan Scott joins CBS News to share what patients told him. CBS […]
The GLP-1 Revolution: How a Diabetes Drug Became the Pharmaceutical Industry’s Hottest Asset
*A data-driven investigation into the clinical trial explosion that’s reshaping modern medicine* Continue reading on Medium »
Tirzepatide is Associated with Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients with Type 2 Diabetes
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown superior efficacy in glycemic control, weight loss, and cardiometabolic outcomes compared to GLP-1 RAs alone. While GLP-1 RAs may offer neuroprotective effects relevant to glaucoma, the impact of dual-incretin therapies like tirzepatide on glaucoma remains unknown. This study investigates […]
Ozempic 2.0! Experts Call GLP-1 Pills a Game-Changer for Weight Loss—Here’s How They Work and When To Expect Them
Post Content